Gamma Secretase (EC 3.4.23.) – Drugs In Development, 2021

According to the recently published report 'Gamma Secretase – Drugs In Development, 2021'; Gamma Secretase (EC 3.4.23.) pipeline Target constitutes close to 21 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes.

Gamma Secretase (EC 3.4.23.) – Gamma secretase is a multi-subunit protease complex, itself an integral membrane protein, that cleaves single-pass transmembrane proteins at residues within the transmembrane domain. The most well-known substrate of gamma secretase is amyloid precursor protein, when cleaved by both gamma and beta secretase, produces a short 39-42 amino acid peptide called amyloid beta whose abnormally folded fibrillar form is the primary component of amyloid plaques found in the brains of Alzheimer's disease patients. Gamma secretase is also critical in the related processing of the Notch protein.

The report 'Gamma Secretase – Drugs In Development, 2021' outlays comprehensive information on the Gamma Secretase (EC 3.4.23.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Gamma Secretase (EC 3.4.23.) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 2, 9 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively.

Report covers products from therapy areas Central Nervous System, Oncology, Ear Nose Throat Disorders, Non Malignant Disorders, Cardiovascular, Genetic Disorders and Metabolic Disorders which include indications Alzheimer's Disease, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Adenoid Cystic Carcinoma (ACC), Benign Tumor, Hearing Disorders, Soft Tissue Sarcoma, Triple-Negative Breast Cancer (TNBC), Acute Sensorineural Hearing Loss, Bile Duct Cancer (Cholangiocarcinoma), Burkitt Lymphoma, Chronic Lymphocytic Leukemia (CLL), Colon Cancer, Congestive Heart Failure (Heart Failure), Down Syndrome, Gastrointestinal Stromal Tumor (GIST), Glioblastoma Multiforme (GBM), Leiomyosarcoma, Leukemia, Metastatic Breast Cancer, Metastatic Hepatocellular Carcinoma (HCC), Natural Killer Cell Lymphomas, Obesity, Solid Tumor and T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for Gamma Secretase (EC 3.4.23.)

– The report reviews Gamma Secretase (EC 3.4.23.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Gamma Secretase (EC 3.4.23.) targeted therapeutics and enlists all their major and minor projects

– The report assesses Gamma Secretase (EC 3.4.23.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Gamma Secretase (EC 3.4.23.) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Gamma Secretase (EC 3.4.23.)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Gamma Secretase (EC 3.4.23.) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Adipo Therapeutics LLC

AlzeCure Pharma AB

Astellas Pharma Inc

Audion Therapeutics BV

Ayala Pharmaceuticals Inc

Eli Lilly and Co

Everfront Biotech Inc

F. Hoffmann-La Roche Ltd

Laminar Pharmaceuticals SA

Merck & Co Inc

NeuroGenetic Pharmaceuticals Inc

Pharchoice Therapeutics Inc

Pipeline Therapeutics Inc

SpringWorks Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Gamma Secretase (EC

3.4.23.) - Overview

Gamma Secretase (EC

3.4.23.) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Gamma Secretase (EC

3.4.23.) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Gamma Secretase (EC

3.4.23.) - Companies Involved in Therapeutics Development

Adipo Therapeutics LLC

AlzeCure Pharma AB

Astellas Pharma Inc

Audion Therapeutics BV

Ayala Pharmaceuticals Inc

Eli Lilly and Co

Everfront Biotech Inc

F. Hoffmann-La Roche Ltd

Laminar Pharmaceuticals SA

Merck & Co Inc

NeuroGenetic Pharmaceuticals Inc

Pharchoice Therapeutics Inc

Pipeline Therapeutics Inc

SpringWorks Therapeutics Inc

Gamma Secretase (EC

3.4.23.) - Drug Profiles

ACD-679 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ACD-680 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AL-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AL-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AUD-1001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

crenigacestat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dibenzazepine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EF-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate PSEN1 for Heart Failure - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSI-34 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LAM-226 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NGP-555 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nirogacestat hydrobromide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Inhibit PSEN1 for Alzheimer’s Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PIPE-505 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RO-7185876 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Beta Secretase and Gamma Secretase for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Gamma Secretase for Hearing Loss - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PSEN1 for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Modulate Gamma Secretase for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UCSD-776890 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gamma Secretase (EC

3.4.23.) - Dormant Products

Gamma Secretase (EC

3.4.23.) - Discontinued Products

Gamma Secretase (EC

3.4.23.) - Product Development Milestones

Featured News & Press Releases

Apr 21, 2021: Ayala Pharmaceuticals announces first patient dosed in phase 1 clinical trial of AL102 in combination with BCMA targeting agent, WVT078, in patients with relapsed/refractory multiple myeloma

Apr 01, 2021: SpringWorks Therapeutics announces dosing of first patient in phase 1b combination study evaluating nirogacestat and Janssen’s BCMA bispecific antibody teclistamab in patients with relapsed or refractory multiple myeloma

Jan 28, 2021: Ayala Pharmaceuticals announces first patient dosed in phase 2 TENACITY clinical trial of AL101 for the treatment of patients with notch-activated triple negative breast cancer

Jan 04, 2021: Ayala Pharmaceuticals to accelerate development of AL102 for the treatment of desmoid tumors in pivotal phase 2/3 study

Sep 18, 2020: Ayala Pharmaceuticals presents positive interim data from phase 2 ACCURACY trial of AL101 for the treatment of recurrent/metastatic adenoid cystic carcinoma with notch activating mutations at ESMO 2020

Sep 16, 2020: SpringWorks Therapeutics announces collaboration with Children’s Oncology Group to conduct a phase 2 clinical trial of nirogacestat in pediatric patients with desmoid tumors and reports publication of nirogacestat case series in pediatric/young adult desmoid tumor patients

Sep 14, 2020: Ayala Pharmaceuticals to host virtual KOL event reviewing interim data presented at ESMO 2020 from ongoing phase 2 accuracy trial of AL101 for the treatment of recurrent/metastatic adenoid cystic carcinoma

Jul 27, 2020: Ayala Pharmaceuticals to present updated data from ongoing phase 2 ACCURACY trial of AL101 for the treatment of R/M adenoid cystic carcinoma at the European Society for Medical Oncology (ESMO) virtual congress 2020

Jul 23, 2020: Pipeline Therapeutics initiates Phase 1/2a clinical trial of PIPE-505 in sensorineural hearing loss

Jul 22, 2020: SpringWorks Therapeutics announces full enrollment of phase 3 DeFi trial evaluating nirogacestat in adult patients with desmoid tumors

Jun 22, 2020: SpringWorks Therapeutics announces dosing of first patient in phase 1b combination study evaluating Nirogacestat and GlaxoSmithKline’s Belantamab Mafodotin for the treatment of Relapsed or Refractory Multiple Myeloma

Mar 18, 2020: SpringWorks Therapeutics announces issuance of new U.S. composition of matter patent to polymorphic form of Nirogacestat, extending patent protection into 2039

Mar 03, 2020: Ayala Pharmaceuticals granted U.S. FDA Fast Track Designation for AL101 for the treatment of recurrent or metastatic adenoid cystic carcinoma

Dec 09, 2019: Researchers present preclinical data showing synergistic activity of Springworks Therapeutics gamma secretase inhibitor (Nirogacestat) with glaxosmithkline’s BCMA antibody-drug conjugate (Belantamab Mafodotin) at the American Society of Hematology (ASH ) Annual Meeting

Sep 30, 2019: Ayala Pharmaceuticals presents encouraging preliminary safety and efficacy data in patients with Recurrent/Metastatic Adenoid Cystic Carcinoma with progressing disease and notch activating mutations from ongoing phase 2 clinical trial at ESMO

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indications, 2021

Number of Products under Development by Indications, 2021 (Contd..1)

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021 (Contd..2)

Number of Products under Investigation by Universities/Institutes, 2021

Products under Investigation by Universities/Institutes, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by Adipo Therapeutics LLC, 2021

Pipeline by AlzeCure Pharma AB, 2021

Pipeline by Astellas Pharma Inc, 2021

Pipeline by Audion Therapeutics BV, 2021

Pipeline by Ayala Pharmaceuticals Inc, 2021

Pipeline by Eli Lilly and Co, 2021

Pipeline by Everfront Biotech Inc, 2021

Pipeline by F. Hoffmann-La Roche Ltd, 2021

Pipeline by Laminar Pharmaceuticals SA, 2021

Pipeline by Merck & Co Inc, 2021

Pipeline by NeuroGenetic Pharmaceuticals Inc, 2021

Pipeline by Pharchoice Therapeutics Inc, 2021

Pipeline by Pipeline Therapeutics Inc, 2021

Pipeline by SpringWorks Therapeutics Inc, 2021

Dormant Products, 2021

Dormant Products, 2021 (Contd..1)

Dormant Products, 2021 (Contd..2)

Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports